Quiescent phenotype of tumor-specific CD8+ T cells following immunization

Vladia Monsurrò, Ena Wang, Yoshisha Yamano, Stephen A. Migueles, Monica C. Panelli, Kina Smith, Dirk Nagorsen, Mark Connors, Steven Jacobson, Francesco M. Marincola

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

In a human melanoma model of tumor antigen (TA)-based immunization, we tested the functional status of TA-specific CD8+ cytotoxic T lymphocytes. A "quiescent" phenotype lacking direct ex vivo cytotoxic and proliferative potential was identified that was further characterized by comparing its transcriptional profile to that of TA-specific T cells sensitized in vitro by exposure to the same TA and the T-cell growth factor interleukin 2 (IL-2). Quiescent circulating tumor-specific CD8+ T cells were deficient in expression of genes associated with T-cell activation, proliferation, and effector function. This quiescent status may explain the observed lack of correlation between the presence of circulating immunization-induced lymphocytes and tumor regression. In addition, the activation of TA-specific T cells by in vitro antigen recall and IL-2 suggests that a complete effector phenotype might be reinstated in vivo to fulfill the potential of anticancer vaccine protocols.

Original languageEnglish
Pages (from-to)1970-1978
Number of pages9
JournalBlood
Volume104
Issue number7
DOIs
Publication statusPublished - 1 Oct 2004
Externally publishedYes

Fingerprint

Immunization
T-cells
Neoplasm Antigens
Tumors
T-Lymphocytes
Phenotype
Interleukin-2
Neoplasms
Chemical activation
Lymphocytes
Cytotoxic T-Lymphocytes
Melanoma
Vaccines
Genes
Cell Proliferation
Gene Expression
Antigens

ASJC Scopus subject areas

  • Hematology

Cite this

Monsurrò, V., Wang, E., Yamano, Y., Migueles, S. A., Panelli, M. C., Smith, K., ... Marincola, F. M. (2004). Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood, 104(7), 1970-1978. https://doi.org/10.1182/blood-2004-02-0525

Quiescent phenotype of tumor-specific CD8+ T cells following immunization. / Monsurrò, Vladia; Wang, Ena; Yamano, Yoshisha; Migueles, Stephen A.; Panelli, Monica C.; Smith, Kina; Nagorsen, Dirk; Connors, Mark; Jacobson, Steven; Marincola, Francesco M.

In: Blood, Vol. 104, No. 7, 01.10.2004, p. 1970-1978.

Research output: Contribution to journalArticle

Monsurrò, V, Wang, E, Yamano, Y, Migueles, SA, Panelli, MC, Smith, K, Nagorsen, D, Connors, M, Jacobson, S & Marincola, FM 2004, 'Quiescent phenotype of tumor-specific CD8+ T cells following immunization', Blood, vol. 104, no. 7, pp. 1970-1978. https://doi.org/10.1182/blood-2004-02-0525
Monsurrò V, Wang E, Yamano Y, Migueles SA, Panelli MC, Smith K et al. Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood. 2004 Oct 1;104(7):1970-1978. https://doi.org/10.1182/blood-2004-02-0525
Monsurrò, Vladia ; Wang, Ena ; Yamano, Yoshisha ; Migueles, Stephen A. ; Panelli, Monica C. ; Smith, Kina ; Nagorsen, Dirk ; Connors, Mark ; Jacobson, Steven ; Marincola, Francesco M. / Quiescent phenotype of tumor-specific CD8+ T cells following immunization. In: Blood. 2004 ; Vol. 104, No. 7. pp. 1970-1978.
@article{d80153b841df4c5a8d7acb56422fbc48,
title = "Quiescent phenotype of tumor-specific CD8+ T cells following immunization",
abstract = "In a human melanoma model of tumor antigen (TA)-based immunization, we tested the functional status of TA-specific CD8+ cytotoxic T lymphocytes. A {"}quiescent{"} phenotype lacking direct ex vivo cytotoxic and proliferative potential was identified that was further characterized by comparing its transcriptional profile to that of TA-specific T cells sensitized in vitro by exposure to the same TA and the T-cell growth factor interleukin 2 (IL-2). Quiescent circulating tumor-specific CD8+ T cells were deficient in expression of genes associated with T-cell activation, proliferation, and effector function. This quiescent status may explain the observed lack of correlation between the presence of circulating immunization-induced lymphocytes and tumor regression. In addition, the activation of TA-specific T cells by in vitro antigen recall and IL-2 suggests that a complete effector phenotype might be reinstated in vivo to fulfill the potential of anticancer vaccine protocols.",
author = "Vladia Monsurr{\`o} and Ena Wang and Yoshisha Yamano and Migueles, {Stephen A.} and Panelli, {Monica C.} and Kina Smith and Dirk Nagorsen and Mark Connors and Steven Jacobson and Marincola, {Francesco M.}",
year = "2004",
month = "10",
day = "1",
doi = "10.1182/blood-2004-02-0525",
language = "English",
volume = "104",
pages = "1970--1978",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Quiescent phenotype of tumor-specific CD8+ T cells following immunization

AU - Monsurrò, Vladia

AU - Wang, Ena

AU - Yamano, Yoshisha

AU - Migueles, Stephen A.

AU - Panelli, Monica C.

AU - Smith, Kina

AU - Nagorsen, Dirk

AU - Connors, Mark

AU - Jacobson, Steven

AU - Marincola, Francesco M.

PY - 2004/10/1

Y1 - 2004/10/1

N2 - In a human melanoma model of tumor antigen (TA)-based immunization, we tested the functional status of TA-specific CD8+ cytotoxic T lymphocytes. A "quiescent" phenotype lacking direct ex vivo cytotoxic and proliferative potential was identified that was further characterized by comparing its transcriptional profile to that of TA-specific T cells sensitized in vitro by exposure to the same TA and the T-cell growth factor interleukin 2 (IL-2). Quiescent circulating tumor-specific CD8+ T cells were deficient in expression of genes associated with T-cell activation, proliferation, and effector function. This quiescent status may explain the observed lack of correlation between the presence of circulating immunization-induced lymphocytes and tumor regression. In addition, the activation of TA-specific T cells by in vitro antigen recall and IL-2 suggests that a complete effector phenotype might be reinstated in vivo to fulfill the potential of anticancer vaccine protocols.

AB - In a human melanoma model of tumor antigen (TA)-based immunization, we tested the functional status of TA-specific CD8+ cytotoxic T lymphocytes. A "quiescent" phenotype lacking direct ex vivo cytotoxic and proliferative potential was identified that was further characterized by comparing its transcriptional profile to that of TA-specific T cells sensitized in vitro by exposure to the same TA and the T-cell growth factor interleukin 2 (IL-2). Quiescent circulating tumor-specific CD8+ T cells were deficient in expression of genes associated with T-cell activation, proliferation, and effector function. This quiescent status may explain the observed lack of correlation between the presence of circulating immunization-induced lymphocytes and tumor regression. In addition, the activation of TA-specific T cells by in vitro antigen recall and IL-2 suggests that a complete effector phenotype might be reinstated in vivo to fulfill the potential of anticancer vaccine protocols.

UR - http://www.scopus.com/inward/record.url?scp=2442707309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442707309&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-02-0525

DO - 10.1182/blood-2004-02-0525

M3 - Article

VL - 104

SP - 1970

EP - 1978

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -